ACURATE neo™

Aortic Valve System

Design

Clinical Evidence

Portfolio

Advanced Education

Clinical Evidence

Boston Scientific Clinical Trials

Investigator Initiated Trials

Boston Scientific Clinical Trials

Explore

PROGRESS PVL Registry

The PRospective Observation of aortic reGuRgitation aftEr TAVI and progreSS over time (PROGRESS) PVL registry
- Kim, WK, Presented PCR e-Course June 25-27, 2020

An open-label, single arm study of 500 patients enrolled at 22 centers in Germany, Canada, the United Kingdom, and Italy between January 2017 and July 2018.

The PROGRESS PVL Registry:

Confirms the high procedural success rate, low overall VARC-2 complication rates, and excellent hemodynamic performance of the ACURATE neo Valve Platform seen across multiple studies and registries.
Shows low core-lab adjudicated paravalvular leakage (PVL) rates (4.3% ≥moderate at discharge, 2.9% (at 1-year) and a significant overall improvement between discharge and 1 year in a paired analysis (P<0.001).

PVL, Paired Analysis

(N = 209, core-lab adjudicated)

Hemodynamic Performance

(mmHg/cm², core-lab adjudicated)

SAVI-TF Post-Market Registry

Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled
in the SAVI-TF registry
- Möllmann H et al.; EuroIntervention 2018;13:e1764-e1770

One-year outcomes of the european post-market registry using the ACURATE neo transcatheter heart valve under real world conditions in 1,000 patients
- Kim et al.; JACC: Cardiovascular Interventions vol. 11, no.1 4, 2 0 1 8; July 23, 2018: 1368–74

European, single-arm, multicenter, all-comers registry, 1,000 patients from
25 centers in Europe directly following CE-marking of ACURATE neo between
October 2014 and April 2016.